LONDON (Reuters) - Bayer AG and Onyx Pharmaceutical Inc.'s key cancer drug Nexavar significantly raises the risk of high blood pressure, U.S. researchers said on Tuesday. Writing in the journal Lancet Oncology, the researchers said people taking the drug generically known as sorafenib should be closely monitored and treated for high blood pressure to prevent cardiovascular complications.
